Outsourcing Clinical Trials: A Global Analytical Guide and Comparative Analysis of International Destinations, with Location Attractiveness IndexArrowhead PublishersMay 1, 2007 215 Pages - SKU: AH1513764 |
- 1 Introduction
- 1.1 China - A Key Emerging Destination for Clinical Trial Outsourcing
- 1.2 India - From Technology Outsourcing to Clinical Trials
- 1.3 Report Scope
- 2 Pharma Productivity: Attitudinal Changes Across the Industry
- 2.1 Key Trends Affecting Pharma Industry
- 2.2 Current Strategies to Stimulate Growth and Control Costs
- 2.3 Reasons for Decreasing Pharma R&D Productivity
- 2.4 The Contract Research Outsourcing Market: Rising
- 2.5 The Rise of Site Management Organizations (SMOs)
- 2.6 Increased Workloads and Shortages of Clinical Resources has US Pharma Looking Abroad
- 2.7 The CRO Share of the Outsourcing Market
- 2.8 Globalization of the CRO Market
- 2.9 CROs and the Need for Improved Patient Recruitment
- 3 Clinical Trials in Central and Eastern Europe (CEE)
- 3.1 Introduction
- 3.2 Location
- 3.3 Target Population
- 3.4 Alternative Medicine
- 3.5 Disease Demographics
- 3.6 Study Investigator Profile
- 3.7 Study Site Characteristics
- 3.8 Regulatory Climate
- 3.9 Study Costs
- 3.10 Clinical Trial Activity
- 3.11 Pharmaceutical Market
- 3.12 Key Market Advantages/Strengths
- 3.13 Key Market Disadvantages/Weaknesses
- 3.14 Recommendations
- 4 Clinical Trials in Asia
- 4.1 Introduction
- 4.2 Location
- 4.3 Target Population
- 4.4 Alternative Medicine
- 4.5 Disease Demographics
- 4.6 Study Investigator Profile
- 4.7 Study Site Characteristics
- 4.8 Regulatory Climate
- 4.9 Study Cost
- 4.10 Clinical Trials Activity
- 4.11 Pharmaceutical Market
- 4.12 Key Market Advantages/Strengths
- 4.13 Key Market Disadvantages/Weaknesses
- 4.14 Report Recommendations
- 5 Clinical Trials in India
- 5.1 Introduction
- 5.2 Location
- 5.3 Target Population
- 5.4 Alternative Medicine
- 5.5 Disease Demographics
- 5.6 Study Investigator Profile
- 5.7 Study Site Characteristics
- 5.8 Regulatory Climate
- 5.9 Study Cost
- 5.10 Clinical Trials Activity
- 5.11 Pharmaceutical Market
- 5.12 Key Market Advantages/Strengths
- 5.13 Key Market Disadvantages/Weaknesses
- 5.14 Recommendations: Strategies for Securing a Share of the Indian Market
- 6 Clinical Trials in Australia and New Zealand (ANZ)
- 6.1 Introduction
- 6.2 Location
- 6.3 Target Population
- 6.4 Alternative Medicine
- 6.5 Disease Demographics
- 6.6 Study Investigator Profile
- 6.7 Study Site Characteristics
- 6.8 Regulatory Climate
- 6.9 Study Costs
- 6.10 Clinical Trial Activity
- 6.11 Pharmaceutical Market
- 6.12 CRO activity
- 6.13 Key Market Advantages/Strengths
- 6.14 Key Market Disadvantages/Weaknesses
- 6.15 Recommendations
- 7 Clinical Trials in Africa
- 7.1 Introduction
- 7.2 Location
- 7.3 Target Population
- 7.4 Alternative Medicine
- 7.5 Disease Demographics
- 7.6 Study Investigator Profile
- 7.7 Study Site Characteristics
- 7.8 Regulatory Climate
- 7.9 Study Costs
- 7.10 Clinical Trial Activity
- 7.11 Pharmaceutical Market
- 7.12 Key Market Advantages/Strengths
- 7.13 Key Market Disadvantages/Weaknesses
- 7.14 Recommendations
- 8 Clinical Trials in Latin America
- 8.1 Introduction
- 8.2 Location
- 8.3 Target Population
- 8.4 Alternative Medicine
- 8.5 Disease Demographics
- 8.6 Study Investigator Profile
- 8.7 Study Site Characteristics
- 8.8 Regulatory Climate
- 8.9 Study Costs
- 8.10 Clinical Trial Activity
- 8.11 Pharmaceutical Market
- 8.12 Key Market Advantages/Strengths
- 8.13 Key Market Disadvantages/Weaknesses
- 8.14 Recommendations
- 9 Clinical Trial Outsourcing Location Attractiveness Index: A Comparative Analysis of International Destinations
- 9.1 Study Cost Indicators
- 9.2 Patient Indicators
- 9.3 Disease Indicators
- 9.4 Clinical Research Indicators
- 9.5 Research Personnel Indicators
- 9.6 Study Site Indicators
- 9.7 Business Environment Indicators
- 9.8 Overall Rank Scores
- Tables
- Table 2.1 Patent Expirations Due on Blockbuster Drugs
- Table 2.2 Ways to Reduce Development Costs for a New Drug
- Table 2.3 Global Spending on Development and Clinical Services Outsourcing*
- Table 2.4 Clinical Study Activity Managed Worldwide by Major CROs
- Table 4.1 Overview of Patients Available for Clinical Trials in China
- Table 4.2 Clinical Trial Considerations in Asia
- Table 4.3 Investigative Sites/Hospitals in Selected Asian Countries
- Table 4.4 Regulatory Approval Times in Select Asian Countries
- Table 4.5 Regulatory Bodies in China Required for Clinical Trial Approval
- Table 4.6 Costs of Clinical Trials in China (in US$)
- Table 5.1 Urban India - Population
- Table 5.2 The Cost of Clinical Trials in India vs. the US
- Table 5.3 Top Pharmaceutical Companies’ R&D and Manufacturing Offshoring Activities and Ramp-up Plans in India
- Table 5.4 Indian CROs
- Table 5.5 Global CROs in India
- Table 5.6 Leading Service Providers
- Table 7.1 United Nations Definition of Major African Regions
- Table 7.2 Leading Causes of Death for Males and Females Aged between 15 to 59 (Estimates for 2000)
- Table 8.1 United Nations Definition of Latin American Regions
- Table 8.2 Selected Country Indicators in Latin America
- Table 8.3 Clinical Trials Information for the Six Key Clinical Trials Location in Latin America*
- Table 8.4 Clinical Trials in Latin America 1966-2003
- Table 8.5 Clinical Trials in Latin America 2006
- Table 8.6 Approved Clinical Studies in Brazil, by Phase
- Table 9.1 Compensation Cost and Infrastructure Cost Indicators, by Country
- Table 9.2 Compensation Cost and Infrastructure Cost Comparative Indices, by Country
- Table 9.3 Study Cost Index and Study Cost Rank Score
- Table 9.4 Patient Indicators, by Country
- Table 9.5 Population Indicator Index and Population Indicator Rank Score
- Table 9.6 Cardiovascular Disease Statistics
- Table 9.7 Pulmonary Disease Statistics
- Table 9.8 Cancer Disease Statitistics
- Table 9.9 Infectious Disease Statistics
- Table 9.10 Cardiovascular Disease Index
- Table 9.11 Pulmonary Disease Index
- Table 9.12 Cancer Index
- Table 9.13 Infectious Disease Index
- Table 9.14 Disease Index
- Table 9.15 Clinical Research Indicators, by Country
- Table 9.16 Clinical Research Index and Clinical Research Rank Score
- Table 9.17 Research Personnel Indicators, by Country
- Table 9.18 Research Personnel Index and Research Personnel Rank Score
- Table 9.19 Study Site Indicators, by Country
- Table 9.20 Study Site Index and Rank Score
- Table 9.21 Business Environment Indicators, by Country
- Table 9.22 Business Environment Index and Rank Score
- Table 9.23 Clinical Trial Global Attractiveness Index
- Graphs
- Graph 2.1 Total Pharma R&D Expenditure (US$ billion)
- Graph 2.2 Total Pharma Clinical Outsourcing Expenditure (US$ billion)
- Graph 2.3 Global Clinical Research Personnel
- Graph 2.4 Pivotal Trial Milestones
- Graph 2.5 Case Report Form Queries/Page Screen
- Graph 2.6 Contract Research Organization Global Industry Revenues
- Graph 2.7 Location of New Offices for US-Based CROs
- Graph 3.1 Fee Partition
- Graph 3.2 Clinical Trials Registered in Western Pharmaceutical Companies in Poland 1995-2001
- Graph 3.3 Clinical Trials Registered by Western Pharmaceutical Companies in Hungary 1992-2000
- Graph 3.4 Drug Sales in the Eight New EU Member States in 2004
- Graph 4.1 Number of Human Clinical Trials in Selected Countries (2006)
- Graph 5.1 Cost Savings of Clinical Trials in India
- Graph 6.1 International Clinical Trials Cost Comparisons in Terms of Overall Pharmaceutical Manufacturing Costs
- Graph 6.2 Mean Fee per Patient (in AU$)
- Graph 6.3 Schemes, Location and Phases of Clinical Trials in Australia
- Graph 7.1 Proposed EDCTP Expenditure (203-2007)
- Graph 8.1 Estimated Annual National Health Expenditure as a Proportion of GDP in Select Latin American Countries
- Graph 8.2 Leading Causes of Death in Latin America
- Graph 8.3 Key Areas of Latin American Investigators’ Expertise
- Graph 8.4 Most Common Pending Issues from the Brazilian Ministry of Health
- Graph 8.5 Therapeutic Breakdown of Current Clinical Research in Argentina
- Graph 8.6 Lilly Argentina’s Clinical Trial Activity (1997-2000)
- Graph 8.7 Pfizer Argentina’s Clinical Research Activity
- Graph 8.8 Sponsors of Clinical Research in Argentina
- Graph 8.9 Total Approved Clinical Studies in Brazil, by Year
- Graph 8.10 Latin American Pharmaceutical Market in 2005 by Key Countries
- Graph 9.1 Compensation Cost Indices
- Graph 9.2 Population Related Indices
- Graph 9.3 Cardiovascular Disease Index
- Graph 9.4 Pulmonary Index
- Graph 9.5 Cancer Index
- Graph 9.6 Infectious Disease Index
- Graph 9.7 Disease Incidence Index
- Graph 9.8 Clinical Research Rank Order
- Graph 9.9 Research Personnel Indicators, Rank Order
- Graph 9.10 Study Site Indices
- Graph 9.11 Business Environment Indices
- Graph 9.12 Clinical Trial Global Attractiveness Index
More Research & Development reports by Arrowhead Publishers
The Global Pain Therapeutics Market Market Analysis, R&D Pipelines and Competitive Landscape by Arrowhead Publishers
One in five people suffer from moderate to severe chronic pain, and one in three is unable or less able to maintain an independent lifestyle ...
The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape by Arrowhead Publishers
The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales. The antibacterial market is set to ...
The Global Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape by Arrowhead Publishers
The global anti-infective market is currently valued at US$66.5 billion with antiviral agents accounting for 24% of sales (excluding vaccines which target viral infectious diseases).
...
Innovations and Trends in Clinical Trials: Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology by Arrowhead Publishers
See all reports like this >> The clinical trials industry has clear potential for strong growth in the future, driven by technological and scientific advances. This trend is complemented by the ...
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Research & Development Reports
- Triple Analysis: Breast Cancer, Lymphoma and Peptides
- Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
- Global Markets for Diabetes Therapeutics and Diagnostics - Focus on the Americas
- Botanical and Plant-Derived Drugs: Global Markets
- Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

